https://ogma.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 MicroRNA: small RNA mediators of the brains genomic response to environmental stress https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:29331 Wed 11 Apr 2018 12:30:03 AEST ]]> Position statement part one: immune function and exercise https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:14499 Wed 11 Apr 2018 10:21:55 AEST ]]> Genome-wide association studies suggest limited immune gene enrichment in schizophrenia compared to 5 autoimmune diseases https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:29042 Wed 11 Apr 2018 09:36:12 AEST ]]> Cross-disorder analysis of schizophrenia and 19 immune-mediated diseases identifies shared genetic risk https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:46890 Tue 06 Dec 2022 12:02:52 AEDT ]]> Immunity and stroke, the hurdles of stroke research translation https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:31275 Thu 13 Jan 2022 10:30:36 AEDT ]]> The effect of disgust on oral immune function https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:17929 Sat 24 Mar 2018 07:56:23 AEDT ]]> Gene expression analysis reveals schizophrenia-associated dysregulation of immune pathways in peripheral blood mononuclear cells https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:20133 Sat 24 Mar 2018 07:51:34 AEDT ]]> Increased inflammatory markers identified in the dorsolateral prefrontal cortex of individuals with schizophrenia https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:28617 Sat 24 Mar 2018 07:38:56 AEDT ]]> Altered neural signaling and immune pathways in peripheral blood mononuclear cells of schizophrenia patients with cognitive impairment: a transcriptome analysis https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:25081 Sat 24 Mar 2018 07:15:04 AEDT ]]> Altered IL-2, IL-6 and IL-8 serum levels in schizophrenia patients with tardive dyskinesia https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:23440 Sat 24 Mar 2018 07:12:55 AEDT ]]> Consensus guidelines for the management of adult immune thrombocytopenia in Australia and New Zealand https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:45844 20 x 109/L, and avoidance of severe bleeding. Steroids are the standard first line treatment, with either 6-week courses of tapering prednisone or repeated courses of high dose dexamethasone providing equivalent efficacy. Intravenous immunoglobulin can be used periprocedurally or as first line therapy in combination with steroids. Changes in management as a result of this statement: There is no consensus on choice of second line treatments. Options with the most robust evidence include splenectomy, rituximab and thrombopoietin receptor agonists. Other therapies include azathioprine, mycophenolate mofetil, dapsone and vinca alkaloids. Given that up to one-third of patients achieve a satisfactory haemostatic response, splenectomy should be delayed for at least 12 months if possible. In life-threatening bleeding, we recommend platelet transfusions to achieve haemostasis, along with intravenous immunoglobulin and high dose steroids.]]> Mon 07 Nov 2022 14:17:09 AEDT ]]> Understanding Food Allergy Through Neuroimmune Interactions in the Gastrointestinal Tract https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:53532 Mon 04 Dec 2023 15:38:04 AEDT ]]> Polycomb repressive complex 2 is a critical mediator of allergic inflammation https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:42107 Fri 26 Aug 2022 11:23:51 AEST ]]> Transcriptomics identifies blunted immunomodulatory effects of vitamin D in people with multiple sclerosis https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:54701 Fri 08 Mar 2024 12:07:53 AEDT ]]>